Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2025)
Historic Income from Non-Controlling Interests for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $15.8 million.
- Amneal Pharmaceuticals' Income from Non-Controlling Interests rose 3231.76% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 3618.6%. This contributed to the annual value of $43.0 million for FY2024, which is 2194.15% up from last year.
- According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Income from Non-Controlling Interests is $15.8 million, which was up 3231.76% from $13.2 million recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Income from Non-Controlling Interests registered a high of $17.8 million during Q2 2023, and its lowest value of -$119.3 million during Q2 2022.
- For the 5-year period, Amneal Pharmaceuticals' Income from Non-Controlling Interests averaged around $208684.2, with its median value being $10.0 million (2024).
- Per our database at Business Quant, Amneal Pharmaceuticals' Income from Non-Controlling Interests tumbled by 77599.75% in 2022 and then skyrocketed by 503411.37% in 2023.
- Quarter analysis of 5 years shows Amneal Pharmaceuticals' Income from Non-Controlling Interests stood at -$14.1 million in 2021, then surged by 89.17% to -$1.5 million in 2022, then soared by 447.87% to $5.3 million in 2023, then soared by 94.89% to $10.3 million in 2024, then soared by 52.46% to $15.8 million in 2025.
- Its Income from Non-Controlling Interests stands at $15.8 million for Q3 2025, versus $13.2 million for Q2 2025 and $12.4 million for Q1 2025.